MedTrace Logo

PG2 Breast Cancer Evaluation in Adjuvant Medicine-Survival Study

NCT07601113 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2026-05-22

No results posted yet for this study

Summary

Astragalus polysaccharides (APS), acting as an immunomodulator, is known to modulate the tumor microenvironment and inhibit tumor growth and progression, thereby suggesting potential as an adjuvant cancer therapy to improve treatment outcomes.

PG2 (APS Injection) has completed a clinical trial (Protocol name: PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance with Chemotherapy among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy , NCT03314805, hereinafter called the parent trial) aimed to show that PG2 treatment among stage II/III breast patients under adjuvant Epirubicin and cyclophosphamide (EC) regimen in reduction of chemotherapy-induced toxicities and encouraging compliance with chemotherapy. This study will further explore whether the addition of PG2 can delay cancer recurrence or metastasis, thereby conferring substantial survival benefits for early breast cancer patients with adjuvant chemotherapy by retrospectively collecting recurrence, metastasis, and survival information from patients enrolled in the parent trial.

Conditions

  • Survival

Interventions

DRUG

Astragalus polysaccharides 500 mg

Adjuvant chemotherapy in combination with PG2

DRUG

Placebo

Adjuvant chemotherapy in combination with Placebo

Sponsors & Collaborators

  • Kun-Ming Rau

    lead OTHER

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07601113 on ClinicalTrials.gov